Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
ConditionHodgkin Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Cologne
About this trial
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care
Eligibility criteria
Qualifiers
age 18-60
advanced stage classical Hodgkin Lymphoma
no previous treatment for cHL
Disqualifiers
Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
Chemotherapy or radiotherapy in medical history
Prior or concurrent disease that prevents treatment according to protocol
Trial design
Treatments tested in this trial
- Pembrolizumab
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov